Quale sarebbe il prezzo per ImmunoGen, Inc. (IMGN)

Il prezzo per ImmunoGen, Inc. (IMGN) è $31.23

Qual è la capitalizzazione di mercato per ImmunoGen, Inc. (IMGN)

La capitalizzazione di mercato per ImmunoGen, Inc. (IMGN) è $6.24B

Utili di ImmunoGen, Inc. (IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.

Anno	Utile	Cambia
Non abbastanza dati per le date fornite.

Anno

Utile

Cambia

Non abbastanza dati per le date fornite.

Azienda	Utile	Differenza negli utili	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Azienda

Utile

Differenza negli utili

Il paese